Observational study to evaluate changes in quality of life (QoL) in patients diagnosed with low risk MDS who are red blood cell (abc) transfusion dependent.
Changes in QoL will be correlated with patient cardiorespiratory function. Cardiac biomarkers and plasma cytokines will also be evaluated.
They must be able to understand the study procedures, comply with them, and consent in writing prior to any specific study procedure.
Must be able to understand the study procedures, comply with them, and give written informed consent prior to any study-specific procedure.
Adult subjects ≥ 18 years of age with a diagnosis of myelodysplastic syndrome.
Very low, low or intermediate IPSS-R risk category.
Subject undergoing any of the following treatments: azacitidine, decitabine, venetoclax, cytotoxic chemotherapy, radiotherapy, arsenic trioxide, interferon or interleukin.
High or very high IPSS-R risk category.
epidermoid or basal cell carcinoma,
carcinoma in situ of the uterine cervix
Fundación para la Investigación Biosanitaria del Principado de Asturias
Lead sponsor
Hospital Universitario Central de Asturias
Collaborator